No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
carboplatin + pemetrexed
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
nivolumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
bevacizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
cisplatin + pemetrexed
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mesothelioma
Mesothelioma
|
GC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mesothelioma
Mesothelioma
|
bevacizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mesothelioma
Mesothelioma
|
cisplatin + raltitrexed
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mesothelioma
Mesothelioma
|
nivolumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
carboplatin + raltitrexed
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
GC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
gemcitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
vinorelbine tartrate
Sensitive: A2 - Guideline
|
BRCA1 mutation
BRCA1 mutation
|
Mesothelioma
Mesothelioma
|
rucaparib
Sensitive: C1 - Off-label
|
BAP1 mutation
BAP1 mutation
|
Mesothelioma
Mesothelioma
|
olaparib
Resistant: C2 – Inclusion Criteria
|
BAP1 mutation
BAP1 mutation
|
Mesothelioma
Mesothelioma
|
tazemetostat
Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
PD-L1 expression
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
nivolumab
Sensitive: C3 – Early Trials
|
WT1 expression
WT1 expression
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
nivolumab + galinpepimut-S
Sensitive: C3 – Early Trials
|
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
PD1 inhibitor
Resistant: C3 – Early Trials
|
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
PD-L1 inhibitor
Resistant: C3 – Early Trials
|
PD-L1 underexpression
PD-L1 underexpression
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
PD1 inhibitor
Resistant: C3 – Early Trials
|
BAP1 negative + BRCA1 mutation
BAP1 negative + BRCA1 mutation
|
Mesothelioma
Mesothelioma
|
rucaparib
Sensitive: C3 – Early Trials
|
BAP1 negative
BAP1 negative
|
Mesothelioma
Mesothelioma
|
rucaparib
Sensitive: C3 – Early Trials
|
MRE11A mutation
MRE11A mutation
|
Mesothelioma
Mesothelioma
|
olaparib
Sensitive: C3 – Early Trials
|
BRCA1 negative
BRCA1 negative
|
Mesothelioma
Mesothelioma
|
rucaparib
Sensitive: C3 – Early Trials
|
BAP1 mutation
BAP1 mutation
|
Mesothelioma
Mesothelioma
|
rucaparib
Sensitive: C3 – Early Trials
|
PD-L1 overexpression
PD-L1 overexpression
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
nivolumab
Sensitive: C4 – Case Studies
|
EML4-ALK I1171N + L1196M + G1202R
EML4-ALK I1171N + L1196M + G1202R
|
Mesothelioma
Mesothelioma
|
lorlatinib
Resistant: C4 – Case Studies
|
EML4-ALK I1171N + L1196M
EML4-ALK I1171N + L1196M
|
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
|
alectinib
Resistant: C4 – Case Studies
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
crizotinib
Sensitive: C4 – Case Studies
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
ABT 263
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
cobimetinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
ceritinib + PF-05212384
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
X-396
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
trametinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
cobimetinib + ceritinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
ceritinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
brigatinib
Sensitive: D – Preclinical
|
STRN-ALK rearrangement
STRN-ALK rearrangement
|
Mesothelioma
Mesothelioma
|
cisplatin + gemcitabine
Resistant: D – Preclinical
|
